MLLT3 and acute myeloid leukemia: In a mouse MLL-AF9 fusion model of AML, an RNAi screen previously identified BRD4 as a potential therapeutic target [19], and in the RN2 cell line derived from these mice, ETS-family DNA-binding motifs are enriched in BRD4 ChIP-seq peaks [20].